The U.S. Centers for Disease Control and Prevention (CDC) announced Wednesday that it plans to launch a series of Phase 3 clinical trials of a new herpes vaccine designed to prevent a third of all new cases of the disease.
The Phase 3 trials will begin in late 2018 and run until 2021.
“The CDC has been very clear: we are committed to taking the most promising vaccines that we can get and we are working on the best path to deliver these vaccines to our communities,” CDC Director Tom Frieden said in a statement.
“The time is now to get this vaccine to the people of the United States.
We will continue to take the next steps in this effort.”
The vaccine is being developed by the Vaccine Alliance, a nonprofit organization that is backed by billionaire John Arnold, who is a director of Pfizer.
The group is led by Dr. John Ioannidis, a former Pfizer vice president and currently a consultant to the vaccine company.
Dr. John F. Anderson, a professor of infectious disease medicine at Johns Hopkins University, is the lead author of the paper that was published in the journal PLOS Medicine.
“We are hopeful that we will be able to achieve clinical trials in 2018,” Anderson told The Washington Post.
Dr. Anderson is the chief of infectious diseases at Johns Johns Hopkins, where the company has developed a vaccine against the coronavirus.
He previously served as director of the Vaccines and Immunizations Division at the Centers for Medicare and Medicaid Services.
In a statement, the CDC said the vaccine was developed to be “in-vivo, safe, and efficacious.”
“We have a lot of great things to offer,” Anderson said.
“This is not the end, but a beginning of the next step.”
It is unclear how much of the vaccine will be given to the general public, though the group is looking to give the vaccine to people aged 18-49.
The new vaccine will also be used for people who have weakened immune systems, such as people who are HIV-positive or who have had a previous reaction to a previous vaccine.
For the Phase 3 trial, which was designed to determine if the new vaccine is safe and effective for people aged 65 and older, CDC officials say they expect to test a total of 2,000 people, including 4,000 who will be enrolled in the study.
The trial is expected to run until 2020.
More on the coronavalvirus: